EZH2 has a Non-Catalytic and PRC2-Independent Role in Stabilizing DDB2 to Promote Nucleotide Excision Repair

Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor outcomes associated with resistance to cisplatin-based chemotherapy. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), which silences transcription through trimethylation of h...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyen, Allyson E., Madden, Matthew Z., Park, Dongkyoo, Minten, Elizabeth V., Kapoor-Vazirani, Priya, Werner, Erica, Pfister, Neil T., Haji-Seyed-Javadi, Ramona, Zhang, Hui, Xu, Jie, Deng, Nikita, Duong, Duc M., Pecan, Turner J., Frazier, Zoë, Nagel, Zachary D., Lazaro, Jean-Bernard, Mouw, Kent W., Seyfried, Nicholas T., Moreno, Carlos S., Owonikoko, Taofeek K., Deng, Xingming, Yu, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305988/
https://www.ncbi.nlm.nih.gov/pubmed/32457468
http://dx.doi.org/10.1038/s41388-020-1332-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305988/
https://www.ncbi.nlm.nih.gov/pubmed/32457468
http://dx.doi.org/10.1038/s41388-020-1332-2

Ejemplares similares